Japanese major’s profit figures for fiscal year just ended will be hit by multiple accounting decisions related to sales, pipeline and partnerships.
Astellas Pharma, Inc. will book an impairment loss totalling JPY58.3bn ($437m) in the fourth quarter of its fiscal year just ended on 31 March, in a decision set to dent its previously forecast profit figures as it adjusts for disappointing sales of kidney disease drug Evrenzo, drops a hearing loss candidate and ends a T-cell deal with a UK partner.
The company’s share price on the Tokyo Stock Exchange opened lower on 12 April following the news, but recovered as investors seemingly
The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.
HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.
Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’
